Ivermectin Treatment Efficacy in Covid-19 High Risk Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021

This article is included in 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
  • I-TECH [Ivermectin Treatment Efficacy in COVID-19 High-Risk Patients] (3 documents)
Loading references information
This is a multicenter study, which is aimed to investigate the efficacy of the Ivermectin drug in high risk COVID-19 patients. This study will compare Ivermectin treatment efficacy with standard of care alone. Target cohort is mild to moderate symptomatic Covid-19 (Stage 2-3), high risk patients aged 50 years and above with comorbidity, who presented to hospitals within first 7 days of illness.
Epistemonikos ID: 0f26b48c02d14a9e4e50cb3b97cb08dca5756d4b
First added on: Jun 11, 2021